Video
Dr. Fuchs Discusses Immunotherapy in Gastric Cancer
Author(s):
Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.
Charles S. Fuchs, MD, MPH, director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital, 2017 Giant of Cancer Care in Gastrointestinal Cancer, discusses immunotherapy in gastric cancer.
Better therapies are needed for patients with advanced gastric cancer, says Fuchs, and immunotherapy could be an option.
PD-L1 expression is seen in gastric cancer, suggesting that immunotherapy agents—such as pembrolizumab (Keytruda)—would be effective in this commonly occurring disease.
Latest CME
View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Jun 19th 2025 - Jul 25th 2025
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Jun 18th 2025 - Jun 19th 2026
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Jun 6th 2025 - Jul 12th 2025
Pembrolizumab Plus Chemoradiation Hits ORR End Point in Unresectable Vulvar Cancer
